PTJ
PRQR icon

Paul Tudor Jones’s ProQR Therapeutics PRQR Stock Holding History

Paul Tudor Jones’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75,000
Closed -$496K – 1870
2021
Q1 		$496K Buy
+75,000
New +$383K 0.01% 1141

Other funds holding PRQR

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Paul Tudor Jones's PRQR Position: Q2 2021 in Review

Paul Tudor Jones sold out of ProQR Therapeutics (PRQR) in Q2 2021, closing a stake of 75,000 shares — an estimated $496K sold.

Paul Tudor Jones first reported a position in PRQR in Q1 2021 and held it in 1 quarter. The position peaked at $496K in Q1 2021. 63 funds tracked by Wall St. Rank hold PRQR as of Q2 2021.

  • Paul Tudor Jones reported no remaining ProQR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 75,000 ProQR Therapeutics shares in Q2 2021, an estimated $496K.
  • Paul Tudor Jones first reported a position in ProQR Therapeutics in Q1 2021 and held it in 1 quarter.
  • Paul Tudor Jones's ProQR Therapeutics position peaked at $496K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2021.

Based on Tudor Investment Corp's 13F filing for Q2 2021, filed 16 Aug 2021.